Paxlovid Improved Long Covid Symptoms in Some Patients, Researchers Report
Published On Jan 6, 2025, 5:01 AM
A recent report examined the effectiveness of Paxlovid in treating long Covid among 13 patients. While nine patients reported some improvement, only five experienced lasting benefits, and four experienced no improvement at all. The study highlights ongoing uncertainty about the best treatments for long Covid, despite research efforts. Paxlovid, an antiviral drug produced by Pfizer, shows potential because of its ability to prevent severe illness during acute Covid infections and its possible role in addressing lingering viral remnants that may contribute to long Covid symptoms.
Stock Forecasts
PFE
Positive
Despite mixed results in recent studies regarding the effectiveness of Paxlovid for long Covid, Pfizer remains a key player in the antiviral market. Investor interest may center on the drug’s potential as ongoing research continues, along with discussions about its broader applications in treating COVID-related conditions.
Related News
RFK Jr.’s Lawyer Has Asked the FDA to Revoke Polio Vaccine Approval
Dec 13, 2024, 5:03 AM
Aaron Siri, who specializes in vaccine lawsuits, has been at Robert F. Kennedy Jr.’s side reviewing candidates for top jobs at the Department of Health and Human Services.
Stock market today: Dow, S&P 500, Nasdaq sink as post-election rally fades, Fed prompts rate-cut rethink
Nov 15, 2024, 1:15 PM
Wall Street is absorbing a jump in retail sales and Jerome Powell's hawkish comments as Trump-fueled optimism starts to wear off.
Health stocks hit after Trump taps RFK for top regulator post
Nov 15, 2024, 10:52 AM
Investors are "spooked" by plan to name a vaccine-sceptic as US health secretary, analysts say.